38.85
0.15 (0.39%)
| Penutupan Terdahulu | 38.70 |
| Buka | 38.94 |
| Jumlah Dagangan | 188,564 |
| Purata Dagangan (3B) | 539,177 |
| Modal Pasaran | 1,853,424,640 |
| Harga / Pendapatan (P/E Ke hadapan) | 59.52 |
| Harga / Jualan (P/S) | 5.69 |
| Harga / Buku (P/B) | 8.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Oct 2024 - 4 Nov 2024 |
| Margin Keuntungan | -32.51% |
| Margin Operasi (TTM) | -14.03% |
| EPS Cair (TTM) | -2.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 89.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 136.91% |
| Nisbah Semasa (MRQ) | 3.34 |
| Aliran Tunai Operasi (OCF TTM) | -1.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.10 M |
| Pulangan Atas Aset (ROA TTM) | -9.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Mirum Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.24% |
| % Dimiliki oleh Institusi | 115.70% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 68.00 (Citigroup, 75.03%) | Beli |
| Median | 58.00 (49.29%) | |
| Rendah | 49.00 (Leerink Partners, 26.13%) | Beli |
| Purata | 58.25 (49.94%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 42.77 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 13 Nov 2024 | 50.00 (28.70%) | Beli | 43.92 |
| Citigroup | 13 Nov 2024 | 68.00 (75.03%) | Beli | 43.92 |
| HC Wainwright & Co. | 13 Nov 2024 | 66.00 (69.88%) | Beli | 43.92 |
| 11 Oct 2024 | 66.00 (69.88%) | Beli | 40.11 | |
| Leerink Partners | 17 Oct 2024 | 49.00 (26.13%) | Beli | 39.32 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |